RemeGen Co., Ltd. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported sales was CNY 1,311.85 million compared to CNY 0.9041 million a year ago. Net income was CNY 964.52 million compared to net loss of CNY 270.69 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.5 HKD | +0.83% | +10.11% | -18.56% |
Apr. 26 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 04 | Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.56% | 3.48B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 9995 Stock
- News RemeGen Co., Ltd.
- RemeGen Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021